http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008037037-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b4514d41110794e2516e6f780848041 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46 |
| filingDate | 2007-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d62264942458600491f85bc5f8d8da5 |
| publicationDate | 2008-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008037037-A3 |
| titleOfInvention | Anti-asthmatic medicine comprising i. a. caffeine, ergotamine, zinc, papaverine, atropine, aminophyyline, glaucine etc. |
| abstract | The anti-asthmatic medicine can be implemented in the field o the human medicine for a treatment of the bronchial asthma and the asthmatic bronchitis. The medicine contains coffeinum purum, ergotamintartarat, zincum sulfuricum papaverinum hydrochloricum, atropinum sulfuricum, aminophyllinum, glaucinum hydrochloricum, kalium sulfaguajacolicum and chlorpyraminum, having quantity proportions [in mgj: coffeinum paru 30,00 to 250,00;' ergotamintartarat 0,25 to 2,00; zincum sulfuricum10,00 to 400,00; papaverinum hydrochloricum 30,00 to 200,00; atropinum sulfuricum 0,25 to 1,00; aminophyllinum 40,00 to 250,00;glaucinum hydrochloricum 30,00 to 250,00; kalium sulfaguajacolicum 100,00 to 600,00; chlorpyraminum 30,00 to 200,00. The medicine has a number of advangates, as follows: even the acutest asthmatic ebullitions are being put under control in the course of 30-40 minutes; prevented is a new appearance of a painful asthmatic respiration and of consequent asthmatic ebullitions for periods of 10-20 and more vears i.e. in practice a treatment of the disease is achieved; prevented are the acute side effects and complications of the corticosteroids; the medicinbe has a good bearing and does not result in complications. |
| priorityDate | 2006-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.